Pamela B Landsman

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
    Pamela B Landsman
    Outcomes Research and Management, US Medical and Scientific Affairs, Merck and Company Inc, PO Box 100, UG2B 74, 351 N Sumneytown Pike, North Wales, PA 19454 2505, USA
    Am J Manag Care 11:621-8. 2005
  2. ncbi Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease
    Soma S Nag
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania, USA
    Am J Cardiol 95:862-4. 2005
  3. ncbi Healthcare utilization in community-acquired pneumonia episodes of care: a comparison across the continuum of managed care
    Pamela B Landsman
    Health and Human Performance, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Med Care 47:1084-90. 2009
  4. ncbi NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
    Charles M Alexander
    Outcomes Research and Management, U.S. Medical and Scientific Affairs, Merck and Co, Inc, West Point, PA, USA
    Diabetes 52:1210-4. 2003
  5. ncbi Metabolic syndrome and hyperglycemia: congruence and divergence
    Charles M Alexander
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania, USA
    Am J Cardiol 98:982-5. 2006
  6. ncbi Pharmacy benefits and the use of drugs by the chronically ill
    Dana P Goldman
    RAND, Santa Monica, Calif 90407 2138, USA
    JAMA 291:2344-50. 2004

Detail Information

Publications6

  1. ncbi Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
    Pamela B Landsman
    Outcomes Research and Management, US Medical and Scientific Affairs, Merck and Company Inc, PO Box 100, UG2B 74, 351 N Sumneytown Pike, North Wales, PA 19454 2505, USA
    Am J Manag Care 11:621-8. 2005
    ..To estimate responsiveness of prescription demand within 9 therapeutic classes to increased cost-sharing compared with constant cost-sharing...
  2. ncbi Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease
    Soma S Nag
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania, USA
    Am J Cardiol 95:862-4. 2005
    ..The overall lipid-lowering therapy treatment rate was 38% and the estimated lipid treatment gap (percent needing treatment who were not receiving it) was 62%...
  3. ncbi Healthcare utilization in community-acquired pneumonia episodes of care: a comparison across the continuum of managed care
    Pamela B Landsman
    Health and Human Performance, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Med Care 47:1084-90. 2009
    ..Compare healthcare utilization and total payments for community-acquired pneumonia (CAP) episodes-of-care among 5 health plan designs spanning the continuum of managed care...
  4. ncbi NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
    Charles M Alexander
    Outcomes Research and Management, U.S. Medical and Scientific Affairs, Merck and Co, Inc, West Point, PA, USA
    Diabetes 52:1210-4. 2003
    ..However, individuals with diabetes without metabolic syndrome had no greater prevalence of CHD compared with those with neither...
  5. ncbi Metabolic syndrome and hyperglycemia: congruence and divergence
    Charles M Alexander
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania, USA
    Am J Cardiol 98:982-5. 2006
  6. ncbi Pharmacy benefits and the use of drugs by the chronically ill
    Dana P Goldman
    RAND, Santa Monica, Calif 90407 2138, USA
    JAMA 291:2344-50. 2004
    ..Many health plans have instituted more cost sharing to discourage use of more expensive pharmaceuticals and to reduce drug spending...